

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 24 June 2003



Patent Application
Docket No. USF-T154X
Serial No. 10/024,019

1645
JB
7/9/03

Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (not yet assigned)
Art Unit : 1645
Applicant(s) : Thomas P. Loughran, Jr., Ravi Kothapalli
Serial No. : 10/024,019
Filed : December 21, 2001
For : Sphingosine 1-Phosphate Receptor Gene, SPRR

RECEIVED

JUN 27 2003

CH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Jeff Lloyd
Patent Attorney

Registration No. 35,589

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

JL/tl

Enclosures as stated above



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/024,019
				Filing Date	December 21, 2001
				First Named Inventor	Thomas P. Loughran, Jr.
				Art Unit	1645
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	USF-T154X

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 00/11166	03-02-2000	Millennium Pharmaceuticals, Inc.		
	F2	WO 01/66742 A2	09-13-2001	Incyte Genomics, Inc.		
	F3	WO 00/31258	06-02-2000	Arena Pharmaceuticals, Inc.		
	F4	EP 1 149 907 A1	10-31-2001	Aventis Pharma Deutschland GmbH		
	F5	WO 99/33972	07-08-1999	Allelix Biopharmaceuticals Inc.		
	F6	WO 97/00952	01-09-1997	Incyte Pharmaceuticals, Inc.		
	F7	WO 99/46277	09-16-1999	Smithkline Beecham Corp.		
	F8					
	F9					
	F10					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
JUN 27 2003
TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0654-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/024,019
				Filing Date	December 21, 2000
				First Named Inventor	Thomas P. Loughran, Jr.
				Group Art Unit	1645
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	USF-T154X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Database EMBL 'ONLINE! Oct. 8, 1999, retrieved from EBI Database accession no. ACO11461 XP002236899 abstract	
	R2	Database EMBL 'ONLINE! Sept. 28, 2001, retrieved from EBI Database accession no. AX244600 XP002236900 abstract (Sequence 26 from Patent W0 01 66742)	
	R3	Database EMBL 'ONLINE! Dec. 6, 2000, retrieved from EBI Database accession no. af317676 XP002236901 abstract	
	R4	AN <i>et al.</i> , "Signaling Mechanisms and Molecular Characteristics of G Protein-Coupled Receptors for Lysophosphatidic Acid and Sphingosine 1-Phosphate", <i>Journal of Cellular Biochemistry Supplements</i> (1998), 31:147-157	
	R5	IM <i>et al.</i> , "Characterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8*", <i>The Journal of Biological Chemistry</i> (2000), 275(19): 14281-14286	
	R6	HLA <i>et al.</i> , "Sphingosine-1-Phosphate Signaling via the EDG-1 Family of G-Protein-Coupled Receptors", <i>Annals New York Academy of Sciences</i> (2000), 905:16-24	
	R7	GLICKMAN <i>et al.</i> , "Molecular Cloning, Tissue-Specific Expression, and Chromosomal Localization of a Novel Nerve Growth Factor-Regulated G-Protein-Coupled Receptor, <i>nrg-1</i> ", <i>Molecular and Cellular Neuroscience</i> (1999), 14: 141-152	
	R8	AN <i>et al.</i> , "Characterization of a Novel Subtype of Human G Protein-Coupled Receptor for Lysophosphatidic Acid", <i>The Journal of Biological Chemistry</i> (1998), 273(14): 7906-7910	
	R9	KOTHAPALLI <i>et al.</i> , "Characterization of a Human Sphingosine-1-Phosphate Receptor Gene (<i>S1P₃</i>) and its Differential Expression in LGL Leukemia", <i>Biochimica et Biophysica Acta</i> (2002), 117-123	
	R10	SEMENZATO <i>et al.</i> , "The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis", <i>Blood</i> (1997), 89(1): 256-260	
	R11	EPSTEIN and BUTOW, "Microarray technology- enhanced versatility, persistent challenge", <i>Current Opinion in Biotechnology</i> (2000), 11: 36-41	
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.